GlassScriptPhysician profile
William Thomas Mcguire
NPI 1255978417
$1,376.70
in general payments reported to CMS, 2019-2025
17 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $287 · 2023: $430 · 2024: $217 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809 · Entertainment: $13.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.26 |
| Entertainment | $13.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $538.57 | 2021-2025 | |
| Lilly USA, LLC | $151.25 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Mylan Specialty L.P. | $121.96 | 2021-2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $105.86 | 2022-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $99.39 | 2022-2025 | Sublocade |
| Abbvie INC. | $68.69 | 2021-2025 | |
| Novo Nordisk INC | $61.50 | 2022-2024 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $43.07 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $38.52 | 2022 | |
| Pfizer INC. | $28.01 | 2021 | |
| Viatris Specialty LLC | $25.39 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $21.39 | 2024 | Uzedy |
| Xeris Pharmaceuticals, INC. | $16.82 | 2023 | Gvoke Hypopen |
| Amgen INC. | $16.76 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.69 | 2024 | Voquezna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $13.47 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Astrazeneca Pharmaceuticals LP | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcguire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.